Idenix commences proof-of-concept study for hepatitis C drug
CAMBRIDGE, Mass. Idenix Pharmaceuticals has started a proof-of-concept study of an investigational drug for hepatitis C currently in mid-stage clinical development, the drug maker said Thursday.
The study will involve eight patients with hepatitis C who have not received previous treatment taking the drug IDX320 in four doses ranging from 50 mg to 400 mg over three days. The drug is currently in phase 2a trials.
“We are encouraged by the results seen to date with IDX320 and are hopeful that future clinical studies will allow us to continue advancing this program with the ultimate goal of treating a wide range of patients infected with HCV,” Idenix chief medical officer Douglas Mayers said.